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Abstract
Background: Cardiac rehabilitation improves health-related quality of life (HRQoL) and reduces hospitalizations in
patients with heart failure, but international uptake of cardiac rehabilitation for heart failure remains low.
Design and methods: The aim of this multicentre randomized trial was to compare the REACH-HF (Rehabilitation
EnAblement in CHronicHeart Failure) intervention, a facilitated self-care and home-based cardiac rehabilitation pro-
gramme to usual care for adults with heart failure with reduced ejection fraction (HFrEF). The study primary hypothesis
was that the addition of the REACH-HF intervention to usual care would improve disease-specific HRQoL (Minnesota
Living with Heart Failure questionnaire (MLHFQ)) at 12 months compared with usual care alone.
Results: The study recruited 216 participants, predominantly men (78%), with an average age of 70 years and mean left
ventricular ejection fraction of 34%. Overall, 185 (86%) participants provided data for the primary outcome. At 12
months, there was a significant and clinically meaningful between-group difference in the MLHFQ score of –5.7 points
(95% confidence interval –10.6 to –0.7) in favour of the REACH-HF intervention group (p¼ 0.025). With the excep-
tion of patient self-care (p< 0.001) there was no significant difference in other secondary outcomes, including
clinical events (p> 0.05) at follow-up compared with usual care. The mean cost of the REACH-HF intervention was
£418 per participant.
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Conclusions: The novel REACH-HF home-based facilitated intervention for HFrEF was clinically superior in disease-
specific HRQoL at 12 months and offers an affordable alternative to traditional centre-based programmes to address
current low cardiac rehabilitation uptake rates for heart failure.
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Introduction
With important gains in mortality achieved through
pharmacological and device therapy in patients with
heart failure with reduced ejection fraction (HFrEF)
over the past decade,1 the focus is increasingly shifting
towards optimizing health-related quality of life
(HRQoL).2 Patients are prepared to trade off longevity
for an improvement in HRQoL,3 and a Cochrane meta-
analysis of exercise-based cardiac rehabilitation in
patients with heart failure reported important improve-
ments in HRQoL and a reduction in rehospitalizations.4
International guidelines consistently recommend group-
or centre-based cardiac rehabilitation for patients with
HFrEF.5–7 However, less than 10% of people with heart
failure in the United States of America and less than
20% in Europe participate in cardiac rehabilitation,8,9
prompting a call to explore newer strategies to improve
participation and explore the effectiveness of more
accessible alternatives to group- or centre-based cardiac
rehabilitation.8
Home-based cardiac rehabilitation programmes can
widen access and have been shown to be as effective as
group- or hospital-based cardiac rehabilitation after
myocardial infarction and coronary revascularization,
and with similar costs.10 The high cost of treating
people with heart failure is well documented,1 but
little evidence (five randomized trials) is available on
the clinical and cost-effectiveness of home-based car-
diac rehabilitation in heart failure.4 Furthermore,
none of the home-based interventions have involved
caregivers or have been co-developed with patients,
caregivers or clinicians. We therefore developed a
novel home-based cardiac rehabilitation intervention
derived from health behaviour change theory – the
Rehabilitation EnAblement in CHronic Heart Failure
(REACH-HF) intervention – for people with heart fail-
ure and their caregivers, which is facilitated by a health-
care professional.11 We hypothesized that addition of
the REACH-HF intervention to usual care would
improve disease-specific HRQoL for patients with
HFrEF at 12 months’ follow-up compared with usual
care alone.
Methods
The REACH-HF trial was conducted and reported in
accordance with the Consolidated Standards of
Reporting Trials guidelines.12 Our full trial protocol
has been published elsewhere.13
Study population and design
The REACH-HF trial was a multicentre, two parallel
group, randomized, superiority trial in men and women
aged 18 years with a confirmed diagnosis of HFrEF on
echocardiography or angiography (i.e. left ventricular
ejection fraction< 45%) within the preceding five years.
Participants who had undertaken cardiac rehabilitation
within 12 months prior to enrolment were excluded, as
were those with a contraindication to exercise testing or
exercise training. The published protocol provides a full
list of patient inclusion and exclusion criteria.13
Participants were randomized to the REACH-HF inter-
vention plus usual care (REACH-HF group) or usual
care alone (control group).
Participants were recruited from primary and second-
ary care settings in four centres in the United Kingdom
(Birmingham, Cornwall, Gwent and York). Participants
were randomly allocated in a 1:1 ratio, stratified by inves-
tigator site and baseline plasma N-terminal proB-type
natriuretic peptide levels ( 2000 vs.> 2000 pg/ml),
using minimization to facilitate balance between the
groups. Randomization numbers were computer gener-
ated and assigned in strict sequence at the point of ran-
domization. To maintain concealment, the Peninsula
Clinical Trials Unit used a password-protected, Web-
based randomization system to allocate participants
after consent was obtained and baseline assessment data
entered. Treatment allocation was open label given the
nature of the intervention, but outcome assessors were
masked to participants’ allocations. We kept a record
of instances when outcome assessors were inadvertently
unmasked by participants during assessment visits. The
trial statistician and all investigators were blinded to the
outcome data and group allocation until after prespeci-
fied statistical analyses were completed and interpretation
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of results was agreed. Between January 2015 and
February 2016, 216 participants were randomized.
The investigation conforms with the principles out-
lined in the Declaration of Helsinki and the trial was
approved by the North West Lancaster Research Ethics
Committee (14/NW/1351). All participants provided
written informed consent.
Study intervention
A detailed description of the REACH-HF intervention,
its development and its theoretical underpinnings is
published elsewhere.11 In the trial, participants in
both the intervention and control groups continued
with medical management and care of heart failure
according to local and national guidelines.7,14 In the
UK, patients with HFrEF are usually seen by a com-
munity heart failure specialist nurse (soon after hospital
discharge or at diagnosis, mainly to optimize drug dos-
ages) and their family doctor, and some are followed up
by a cardiologist. Most patients with heart failure do
not undertake cardiac rehabilitation.
The REACH-HF intervention is an evidence-
informed, patient-centred, theory-based, self-care sup-
port programme uniquely co-developed with key stake-
holders – patients, caregivers and clinicians. This
comprehensive intervention includes four core elements
(see Figure S1 in the Supplementary Material online):11,13
1. REACH-HF manual for patients with a choice of
two structured exercise programmes: a chair-based
exercise and a progressive walking training pro-
gramme. Patients were advised to exercise 3 times
per week, starting from their own personal level and
gradually building up over 2–3 months in time/dis-
tance/walking pace.
2. Patient ‘Progress Tracker’ – an interactive booklet
designed to facilitate learning from experience to
record symptoms, physical activity and other actions
related to self-care. Patients recorded: (1) how long/
far they plan to walk, (2) whether they have done it,
(3) how it felt to identify whether they should be
moving up or down in effort next time and (4)
their weekly steps per minute (pace).
3. ‘Family and Friends Resource’ – a manual for use by
caregivers aimed to increase their understanding of
heart failure and caregiver physical and mental well-
being.
4. Facilitation by cardiac nurses or physiotherapists,
who attended a three-day training course on the
use of person-centred counselling and how to tailor
the intervention for the patient and their caregiver.
The intervention was delivered at the patient’s home
via a mixture of face-to-face and telephone contacts
over 12 weeks. The first contact was made by the facili-
tator and future contacts were agreed by the patient and
the facilitator at a mutually convenient time. Patient
adherence to the intervention was defined as attendance
at the first face-to-face contact with the facilitator and at
least two facilitator contacts thereafter – at least one of
which must have been face to face.
Usual care
Given that the majority of heart failure patients do not
receive cardiac rehabilitation,8,9 usual care in this trial
was a no cardiac rehabilitation approach that included
medical management according to national and local
guidelines, including specialist heart failure nurse
care.7 Both REACH-HF and control groups received
this usual care.
Outcome measures
The primary outcome was disease-specific HRQoL at 12
months measured using the Minnesota Living with
Heart Failure Questionnaire (MLHFQ).15 Secondary
outcomes were death, hospitalization, generic quality
of life (five-dimension EuroQol (EQ-5D-5L) scale),16
psychological wellbeing (Hospital Anxiety and
Depression Scale (HADS)),17 exercise capacity (incre-
mental shuttle walk test)18 and physical activity assessed
using a GeneActiv accelerometer.19 Additional second-
ary measures included the HeartQoL questionnaire20
and Self-Care of Heart Failure Index.21
Outcome data were collected from participants during
three clinic visits at baseline and four and 12 months and
by postal questionnaire at six months. At the baseline
clinic visit, after obtaining written consent, we collected
sociodemographic data and information on past medical
history from the participants’ hospital and primary care
records, including key comorbidities, New York Heart
Association classification,22 concomitant cardiac drugs
and presence of implantable cardiac devices.
Adherence to intervention protocols by the facilita-
tors was ascertained through audio recordings of
interviews and a fidelity checklist created as part
of the intervention development.11,13 The findings of
the intervention fidelity assessment are summarized in
Supplementary Table S1.
Serious adverse events were recorded and assessed
for their relatedness to the trial processes or the
REACH-HF intervention. Adverse events and reac-
tions were regarded as serious if they resulted in
death, were life threatening or required hospitalization.
All serious adverse events were reported to the ethics
and data monitoring committees.
The use of care services, including those provided by
healthcare professionals in the community and
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secondary care, was documented at each follow-up visit
by participants completing healthcare resource-use
questionnaires and by collection of data on concomi-
tant drug usage. A detailed cost-effectiveness analysis
will be presented elsewhere.
Statistical analysis
The sample size was based on an effect size that repre-
sented the minimal clinically important difference in
our primary outcome measure – that is, five points on
the MLHFQ.15 With a type I error of 0.05 and power of
90%, 85 participants per group were required to detect
a five-point difference in the MLHFQ score, assuming a
standard deviation (SD) of 10.4,23 Assuming an attri-
tion rate of 20% (in accordance with the level of attri-
tion seen in previous trials),10 108 participants were
required per group.
All statistical analyses were conducted to a predefined
analysis plan agreed in advance with the trial manage-
ment group, trial steering committee and data manage-
ment committee. Baseline sociodemographic and health-
related variables are reported descriptively by treatment
arm. The primary analyses for all participant outcomes
were based on a between-group, intention-to-treat basis
in participants with complete outcome data at 12
months. Outcomes were analysed using linear regression
methods, adjusting for stratification variables and base-
line score of the outcome variable, where applicable.
Secondary analyses were undertaken on participant out-
comes as repeated-measures analysis using all follow-up
assessment points (four, six and 12 months). In addition,
we did a per-protocol analysis and estimated complier
average causal effects analysis of the primary outcome
using 12-month follow-up data. We used our definition
of adherence to the REACH-HF intervention (see above
under ‘Study intervention’) to specify the per-protocol
population.
Multiple imputation methods were used as a sensi-
tivity analysis to address the issue of missing outcome
data at follow-up. The following predefined subgroups
were assessed using interaction terms: the two mini-
mization variables used in randomization (centre and
N-terminal proB-type natriuretic peptide) plus time
since diagnosis of heart failure and presence of partici-
pating caregiver.
Serious adverse events are presented descriptively by
treatment arm. All between-group outcome compari-
sons are presented as mean difference with 95% confi-
dence interval (CI). No correction of p values for
multiplicity of testing was undertaken. However, the
primary outcome analysis was done before all other
analyses, and the p values of all subsequent analyses
were interpreted in the context of multiple testing. No
interim analyses were performed.
Unit costs were applied to resource use reported at
the participant level to estimate the delivery costs asso-
ciated with the REACH-HF intervention.24 Costs are
reported in pounds sterling (£) for 2016. All analyses
were performed using Stata version 14.1.
Results
Trial population and interventions
The 216 participants were randomly allocated to the
REACH-HF group (n¼ 107) and control group
(n¼ 109) (Figure 1). Overall, 92 (86%) participants in
the REACH-HF group and 93 (85%) in the control
group provided data for the primary outcome. Drop
out was the result of death (n¼ 8) or withdrawal
(n¼ 20) – 15 participants did not wish to continue,
three were uncontactable and two were too unwell.
Participants were predominantly male (78%) and
New York Heart Association class II (59%), with an
average age of 70 years and mean left ventricular ejection
fraction of 34%. Patient-level characteristics at baseline
were well balanced between the groups, apart from more
frequent cardiac comorbidity (history of myocardial
infarction and atrial fibrillation) and, consequently,
higher Charlson comorbidity score in the control
group (Table 1).25 Mean baseline MLHFQ scores for
the REACH-HF group were higher (poorer) than for
the control group, but secondary baseline outcomes
were similar for the two groups (Tables 2 and 3).
Of the 107 patients randomized to the REACH-HF
group, 96 (90%) met our definition of intervention
adherence.
Primary outcome: disease-specific HRQoL
At 12 months, MLHFQ total scores improved in the
REACH-HF group but did not change in the control
group, with a significant between-group difference of –
5.7 points (95% CI –10.6 to –0.7) in favour of the
REACH-HF group (p¼ 0.025; Table 2). This difference
was also consistent across per-protocol, complier average
causal effects, multiple-imputation and repeated-measure
analyses. The MLHFQ physical score also differed signifi-
cantly in favour of the REACH-HF group (mean differ-
ence at 12 months –3.2 (95% CI –5.7 to –0.6, p¼ 0.016))
but the MLHFQ emotional score did not (–0.8 (–2.2 to
0.6), p¼ 0.273). A post-hoc analysis showed that 48 (52%)
participants in the REACH-HF group and 31 (33%) in the
control group achieved a reduction of5MLHFQ points.
Secondary outcomes
The maintenance score on the Self-Care of Heart
Failure Index, a measure of self-care, was in favour of
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1161 approached
578 provided no response
177 excluded 
12 no response
37 excluded 
136 excluded 
5 excluded 
9 did not meet inclusion criteria
22 declined participation 
6 other reasons 
52 did not meet inclusion criteria
78 declined participation 
2 died 
4 other reasons 
3 did not meet inclusion criteria
2 withdrawn 
14 discontinued 
4 deaths 
10 withdrawals 
18 did not meet inclusion criteria
159 declined participation 
406 provided with study
 information 
357 pre-screened
221 attended baseline visit 
216 participants randomly assigned 
107 assigned to 
REACH-HF 
96 received per
 protocol intervention* 
14 discontinued
4 deaths
10 withdrawals
92† included in primary
analysis 
93† included in primary
 analysis 
109 assigned to
control 
Figure 1. Trial profile.
*Per protocol: REACH-HF participant must attend first face-to-face contact with facilitator and at least two facilitator contacts
thereafter, at least one of which must be face-to-face.
yOne REACH-HF and two control participants had completed questionnaires insufficiently to allow scoring of primary outcome.
REACH-HF: Rehabilitation EnAblement in CHronic Heart Failure
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the REACH-HF intervention group at 12 months
(p< 0.001). Within-group improvements from baseline
were seen in the REACH-HF group for HADS anxiety
and depression, incremental shuttle walk test and Self-
Care of Heart Failure Index (management and confi-
dence) but did not reach statistical significance com-
pared with control at 12 months. No differences were
seen in the other secondary outcomes, that is, EQ-5D,
HeartQoL and physical activity (Table 2). Similar pat-
terns of primary and secondary results were seen at four
and six months. We found no evidence of a significant
subgroup treatment interaction on the primary out-
come at 12 months by N-terminal proB-type natriuretic
peptide level, presence of caregiver, recruitment site or
duration of heart failure (see Supplementary Table S2).
Table 1. Baseline characteristics. Data are n (%) unless other-
wise indicated; percentages may not sum to 100 because of
rounding.
Characteristic
REACH-HF
n¼ 107
Control
n¼ 109
Mean (SD) age, yearsa 69.7 (10.9) 69.9 (11)
Female sex 26 (24) 21 (19)
Median (IQR)
BMI, kg/m2 b
28.1 (25.3–32.4) 28.0 (25–32.2)
Main activity
Retired 81 (76) 83 (76)
In employment or
self-employment
18 (17) 17 (16)
Living alone 28 (26) 22 (20)
Ethnic origin
White 100 (93) 104 (95)
Other, Black, Asian, other 7 (7) 5 (5)
NYHA status
Class I 24 (22) 19 (17)
Class II 63 (59) 63 (58)
Class III 20 (19) 26 (24)
Class IV – 1 (1)
Ischaemic aetiology of HF 48 (45) 50 (46)
Time since diagnosis of HF, years
<1 35 (33) 35 (32)
1–2 18 (17) 20 (18)
>2 54 (51) 54 (50)
Median (IQR) LVEF, %c 34.5 (25–39) 33 (27–36.3)
NT-pro-BNP level, pg/ml
2000 84 (79) 86 (79)
>2000 23 (22) 23 (21)
Current smoker 6 (6) 6 (6)
Comorbidities, past or present
Diabetes mellitus 26 (24) 25 (23)
Myocardial infarction 29 (27) 38 (35)
Hypertension 45 (42) 42 (39)
Chronic renal impairment 14 (13) 19 (17)
Arthritis, osteoarthritis
or rheumatoid
45 (42) 35 (32)
Atrial fibrillation or
atrial flutter
48 (45) 60 (55)
COPD 8 (8) 9 (8)
Depression 27 (25) 23 (21)
Charlson comorbidity
score> 3d
12 (11) 26 (24)
Baseline use of drugs
Beta-blocker 90 (84) 90 (83)
Angiotensin II receptor
antagoniste
31 (29) 24 (22)
ACE inhibitore 68 (64) 74 (68)
Loop diuretic 70 (65) 68 (62)
(continued)
Table 1. Continued
Characteristic
REACH-HF
n¼ 107
Control
n¼ 109
Aldosterone antagonist
Digoxin
64 (60)
20 (19)
52 (48)
14 (13)
Baseline use of devices
ICD 10 (9) 11 (10)
CRT 10 (9) 5 (5)
Combined CRT/ICD 5 (5) 4 (4)
Pacemaker 11 (10) 11 (10)
Location
Cornwall, England, UK 30 (28) 31 (28)
Gwent, Wales, UK 23 (22) 23 (21)
Birmingham, England, UK 27 (25) 28 (26)
York, England UK 27 (25) 27 (25)
Caregiver present at
randomization
53 (50) 44 (40)
REACH-HF: Rehabilitation EnAblement in CHronic Heart Failure; SD:
standard deviation; IQR: interquartile range; BMI: body mass index;
NYHA: New York Heart Association; HF: heart failure; NT-pro-BNP:
N-terminal proB-type natriuretic peptide; LVEF: left ventricular ejection
fraction; COPD: chronic obstructive pulmonary disease; ICD: implanta-
ble cardioverter defibrillator; CRT: cardiac synchronization therapy
device; UK: United Kingdom.
aNational Audit of Cardiac Rehabilitation (NACR) 2013–2014 data for
comparison: total mean (SD) age in NACR¼ 67 (13) years, mean age for
patients with heart failure¼ 69 (13) years.
bNumerical values for body mass index available for 215 participants
(REACH-HF, n¼ 107; control, n¼ 108).
cNumerical values for LVEF available for 156 participants (REACH-HF,
n¼ 76; control, n¼ 80). Categorical data collected for 60 participants.
All participants had an ejection fraction <45% or systolic dysfunction.
dFor the REACH-HF trial, we calculated the Charlson comorbidity score
but not the Charlson comorbidity index or Charlson comorbidity
adjusted life expectancy, as some of our patient population were older
than 80 years, which is the limit for these additional scores.
ePatients who were intolerant to angiotensin-converting enzyme
inhibitor were on angiotensin II receptor antagonist (e.g. losartan,
candesartan).
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Over the 12 months of the trial, eight (4%) partici-
pants died: four deaths in each group and four deaths
related to heart failure (one REACH-HF, three con-
trols). In the REACH-HF group, 19 participants had
at least one hospital admission during follow-up to 12
months compared with 24 patients in the control group
(odds ratio (OR) 0.72 (95% CI 0.35 to 1.51), p¼ 0.386).
Three REACH-HF versus six control patients experi-
enced one or more hospital admissions related to heart
failure (0.56, 0.13 to 2.33, p¼ 0.422). Overall, there
were 33 admissions (four related to heart failure) in
the REACH-HF group and 35 (10 related to heart fail-
ure) in the control group. The independent data moni-
toring committee considered none of the 37 serious
adverse events in the REACH-HF to be related to the
intervention.
Costs
To calculate costs, facilitator contact sheets were com-
pleted at 12 months and were available for 94 (98%)
participants in the REACH-HF intervention group.
The mean number of facilitator contacts was 6.5 per
participant, and total contact time and non-contact
time inputs were 5.3 and 2.9 h per participant, respect-
ively, with overall time input at 8.25 h per participant.
Taking into account these contact times, facilitator
training, and travel and consumables, the mean total
cost for delivery of the REACH-HF intervention was
estimated at £418.39 per participant (Supplementary
Table S3).
Discussion
In this randomized, multicentre trial, participants with
HFrEF who received the novel REACH-HF home-
based cardiac rehabilitation intervention for 12 weeks
in addition to usual care had superiority in disease-spe-
cific HRQoL and self-management at 12 months com-
pared with usual care alone. The magnitude of
improvement in total MLHFQ (mean between group
difference –5.7 (95% CI –10.6 to –0.7) points) was not
only statistically significant but also clinically meaning-
ful (i.e. a reduction 5 points).16 The MLHFQ score is
a key outcome indicator for patient well-being that has
been shown to be independently related to survival.26
The cost of the REACH-HF intervention (£418.39 per
participant) falls within the National Health Service
tariff for cardiac rehabilitation in England of £477 per
patient.27
The REACH-HF intervention was also associated
with better patient ratings of self-care maintenance
assessed using the Self-Care of Heart Failure Index,
indicating enhanced engagement in activities such as
Table 3. Secondary objective outcomes at baseline and follow-up. Data are mean (standard deviation, n) unless otherwise indicated.
Outcome
Baseline
Follow-up
Four months 12 months
REACH-HF Control REACH-HF Control REACH-HF Control
Between-group
difference p value
ISWT, m 262.3
(153.4, 99)
239.7
(152.4, 103)
328.5
(181.3, 66)
294.3
(215.5, 75)
328.5
(181.3, 66)
294.3
(215.5, 75)
0.1
(–33.3 to 33.5)
0.995
Number of days/week with at
least 10min/day activity
>100 milli-ga
5.8
(2.3, 99)
5.9
(1.9, 103)
5.6
(2.4, 78)
5.5
(2.6, 84)
5.6
(2.4, 78)
5.5
(2.6, 84)
0.2
(–0.4 to 0.7)
0.601
Average time/day (min)
20 milli-ga 1104
(102, 99)
1106
(114, 103)
1107
(110, 88)
1092
(116, 93)
1092
(124, 78)
1103
(118, 84)
–7 (–29 to 15) 0.534
21–40 milli-ga 141
(35, 99)
136
(35, 103)
140
(35, 88)
138
(30, 93)
142
(39, 78)
138
(34, 84)
–1 (–9 to 8) 0.880
41–60 milli-ga 80
(25, 99)
80
(27, 103)
80
(27, 88)
82
(26, 93)
81
(30, 78)
81
(28, 84)
0 (–6 to 6) 0.901
61–80 milli-ga 45
(21, 99)
46
(21, 103)
45
(22, 88)
48
(22, 93)
48
(23, 78)
46
(22, 84)
2 (–2 to 5) 0.372
81–100 milli-ga 26
(16, 99)
27
(16, 103)
26
(16, 88)
28
(17, 93)
>100 milli-ga 42
(34, 99)
46
(40, 103)
43
(37, 88)
51
(46, 93)
a1000 milli-g¼ 1 g¼ 9.81m/s2,< 40 milli-g is approximately equivalent to sedentary activities such as sitting, lying and 100 milli-g is approximately
equivalent to activities undertaken at a moderate to vigorous intensity.
REACH-HF: Rehabilitation EnAblement in CHronic Heart Failure; ISWT: incremental shuttle walk test; milli-g: milli-gravity unit
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monitoring their weight and increased exercise, looking
for signs of fluid retention and using a system to help
remember daily drugs.21
The results of our trial are consistent with existing
evidence on the impact of cardiac rehabilitation for
heart failure. The 2014 Cochrane meta-analysis of exer-
cise-based cardiac rehabilitation included 33 trials and
reported a mean benefit in MLHFQ score of –5.8 (95%
CI –9.2 to –2.4) points (p¼ 0.0007) compared with con-
trol.4 However, it is important to note that most of this
evidence came from trials of hospital- and centre-based
models of cardiac rehabilitation, as only six of the
included trials (413 participants) assessed cardiac
rehabilitation undertaken exclusively in a home-based
setting.4 Furthermore, our findings are in keeping with
recent studies that support the use of home-based inter-
ventions as an alternative to centre-based cardiac
rehabilitation.28,29 Mobile and internet modes of deliv-
ery may offer the opportunity to improve cardiac
rehabilitation uptake in the elderly.30
We believe that this study is the first randomized
trial of a home-based cardiac rehabilitation interven-
tion for heart failure derived from health behaviour
change theory and that was co-developed with patients,
caregivers and clinicians. We recently published the
findings of a single centre pilot trial which supported
the feasibility and acceptability of the REACH-HF
intervention in heart failure patients with preserved
ejection fraction (HFpEF) and indicates that it would
be possible to recruit and retain participants in a full
randomized trial of our intervention in patients with
HFpEF.31
This multicentre trial in patients with HFrEF
recruited to target, had excellent intervention adherence
(90%) and had a relatively low level of attrition
(< 15% loss) over the 12 months of participant
follow-up. There are a number of possible explanations
for the lack of a significant between-group difference in
other outcomes. First, participants may have insuffi-
ciently engaged with the REACH-HF intervention to
stimulate an improvement in outcomes. For example,
failure to adequately engage in the exercise training
programme would explain the lack of between-group
difference in exercise capacity and physical activity.
Second, the trial was not formally powered to detect
differences in secondary outcomes, in particular clinical
events. Third, REACH-HF is a comprehensive, multi-
factorial intervention, with individual patients likely to
have experienced different pathways to improved
HRQoL, which may include reduced stress or anxiety;
improved pacing of physical activity, exercise capacity,
or sleep quality; and better medication management. In
addition, the baseline characteristics of our study popu-
lation indicated high levels of comorbidity. The lack of
impact on exercise capacity and physical activity may
therefore be attributed to the ‘heavy burden of comor-
bid disease’ that can affect outcomes in older patients
with heart failure.32 For example, substantive numbers
of patients had atrial fibrillation/flutter (50%) and
osteoarthritis or rheumatoid arthritis (37%), which
could have limited the participants’ intensity and fre-
quency of exercise and physical activity. Finally, there
is a growing evidence base demonstrating the limited
sensitivity of the EQ-5D in mild-to-moderate heart fail-
ure.33–35 Consistent with our study, the HF-ACTION
study found no difference in the EQ-5D utility score
after exercise-based cardiac rehabilitation compared
with control at 12 months.35 In contrast, the EQ-5D
has been shown to be a valid and sensitive measure in
patients with advanced heart failure.2
Study limitations
This study had potential limitations. First is the lack of
blinding – given the nature of the intervention and con-
trol, we could not mask participants to treatments, so
our results may reflect patient expectation bias.
However, we used self-reported outcome measures and
outcome assessor blinding procedures to reduce
researcher assessment bias. Second, around 15% of
data were missing for the primary outcome measure at
follow-up. However, our sensitivity analyses show that
the between-group inferences in our trial were robust to
data imputation. To take account of the observed base-
line between-group imbalance, we adjusted all analyses
for baseline outcome scores and the presence of cardiac
morbidity (myocardial infarction, atrial fibrillation and
atrial flutter). Third, the assessment of adherence is
notoriously challenging in home-based interventions
(given the self-direct nature of the intervention, we
were not a able to capture consistent patient-level data
on their level of intervention adherence, such as their
exercise training programme).36
Conclusions
The REACH-HF home-based cardiac rehabilitation
intervention for the management of HFrEF results in
superior and clinically important improvements in dis-
ease-specific HRQoL and self-management. These find-
ings support the benefits of an affordable, novel home-
based cardiac rehabilitation intervention that offers
patients, clinicians and healthcare commissioners an
additional option to centre-based cardiac rehabilitation
to address current low rates of uptake.
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